PPT-A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice

patients with advanced breast cancer and a germline BRCA mutation Jennifer K Litton  Hope S Rugo  Johannes Ettl Sara Hurvitz Anthony Gonçalves KyungHun Lee . Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Opinion. 55 year-old woman with . recurrent . ovarian cancer. Underwent an optimal . cytoreductive. surgery and placement of an intraperitoneal catheter. Disease progressed through multiple lines of chemotherapy. and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Methods in Clinical Cancer Research. February 12, 2015. Effective incorporation of . biomarkers into phase II trials. There are many roles for biomarkers in Phase II trial designs.. Examples of biomarkers with pivotal role in development of new therapies. Assistant Professor. Department of Internal Medicine – Hospital Medicine Division. Medical Director – UNM Anticoagulation Clinic. Co-Director Antithrombotic Stewardship. Roadmap. Direct oral anticoagulants. Niraparib. and . Temozolomide. in Patients with Previously Treated, incurable Ewing Sarcoma . Co-Principal Investigators: . Sandra . Strauss, MD, PhD. University College London. Rashmi. . Chugh. , MD. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. PARP Inhibitors: What Do We know?. PARP Inhibitors: What Do We Know? (cont). PARP Inhibitors: What Don't We Know ?. SOLO-1: Study Rationale and Design. [a]. Primary Endpoint and Other . R. esults. Time to Second Progression or Death (. Program Overview . Discussion Outline. DNA Repair. ABCs of DNA Repair. DNA Repair Defects in Cancer. DNA Repair Defects Can Be an Achilles' Heel. Synthetic Lethality and Cancer DNA Repair Defects. Increased Sensitivity of . Carbohydrate absorption inhibitors α - glucosidose inhibitors Acarbose : Dose Adverse events Relatively complex network controlling PPG: Determinants of PPG PPG Pre-prandial glycaemic level Meal size and meal content Prof JG . Hakim, . Parirenyatwa. . CRS . Leader. Annual Research . Day; 8. th. . April 2016. TB- A Global Problem. TB Transformative Science Group (TB TSG). Agenda. Treatment & prevention of TB with or without HIV co-infection. I Patients Rights Advance Directives and Ownership Notification Form for Mississippi Valley Surgical Center the Notification Form this ethodology, facilitate therapeutic trials and harmonise the treatment of vasculitis within the EC. A first r ANCA-associated system d its renal-limited variant, renal-lim M - generalised disease and Outline. Review of a phase I trial. What is a phase II trial?. Phase II trial process. Standard trial designs. Innovative trial designs. Phase II trial examples. Guess that trial. Phase II thalidomide study.